Abstract:Hepatitis C virus (HCV) infection is a global health problem that impacts approximately 180 million individuals. Until recently the current therapy for treating HCV infection has been regular injections of pegalated a-interferon (PEG-IFN) with daily oral administration of ribavirin (RBV). However, PEG-IFN/RBV treatment is only effective for only 50% of genotype 1 patients and associated with significant adverse effects including fatigue, hemolytic anemia, depression, and flu-like symptoms. Therefore, the search for direct acting antivirals (DAAs) that are safe and effective has become an urgent endeavor. HCV NS5B polymerase, an essential enzyme for the HCV RNA replication, has emerged as an attractive and validated target for the direct HCV therapeutic intervention. Since NS5B polymerase needs a divalent metal ion as a cofactore in the active site for its catalytic function, the metal chelation motif-containing quinolone-3-carboxylic scaffold has been explored as a new class of non-nucleoside NS5B inhibitors. Two groups have recently reported a preliminary structure-activity relationship (SAR) study on the 4-quinolone-3-carboxylic acids as HCV NS5B inhibitors, just focused on the N-1, C-3 and C-6/7 substitutions. Based on the binding mode revealed by the cocrystal structure of the quinolone inhibitor bound to the NS5B enzyme, for the first time we proposed to introduce a hydrophobic group at C-2 position on the quinolone ring to improve the anti-HCV potency. By making use of the new method to synthesize 2-substituted quinolone-3-carboxylic acid derivatives recently developed by our group, we conducted a comprehensive SAR study on the 2-aryl-3-carbonylquinolone-based non-nucleoside inhibitors of HCV NS5B polymerase. Starting from the readily accessible amides and 3-oxo-3-arylpropanoates, structurally diverse 2-substituted quinolone-3-carboxylic acid derivatives were efficiently furnished by a tandem addition-elimination reaction/nucleophilic aromatic substitution reaction via an imine-enamine intermediate. The anti-HCV potency and cytotoxicity were evaluated in the HCV-infected host cells Huh7.5.1 assay system. To our delight, the incorporation of a hydrophobic aryl group into 2-position of the quinolone core really enhanced the inhibitory activity against the HCV replication in the host cells with a 2-fold selectivity over the cytotoxicity. Meanwhile, a small size hydrophobic group at N-1 position was favored for the 2-arylquinolone-derived NS5B inhibitors. Further structural variation was investigated on the C-3 and C-7 substituents, with an aromatic ester and an N-methyl piperazine being an optimal moiety, respectively. The global structural optimization at positions N-1, C-2, C-3 and C-7 resulted in the discovery of novel 2-aryl substituted quinolone inhibitors with low micromolar EC50 values to inhibit the replication of the HCV RNA in the host cell Huh7.5.1 and therapeutic indices of 2 similar to 6, providing a new promising lead for the further development into anti-HCV drug candidates.

Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors

Recent Advances on the Synthesis of Hepatitis C Virus NS5B RNA-dependent RNA-polymerase Inhibitors.

Small Molecule NS5B RdRp Non-Nucleoside Inhibitors for the Treatment of HCV Infection: A Medicinal Chemistry Perspective.

HCV Non-Nucleoside NS5B Polymerase Inhibitors

Recent Progress of Non-Structural 5A Protein(ns5a) Inhibitors As Anti-Hepatitis Virus C Agents

New Non-Nucleocide Ns5b Protein Inhibitors For The Treatment Of Chronic Hepatitis C Infection

The Changing Face of Hepatitis C: Recent Advances on Hcv Inhibitors Targeting Ns5a

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

2-Aryl-3-carbonylquinolones: Design, Synthesis and Biological Evaluation of Novel Hcv Ns5b Polymerase Inhibitors

Recent advancement in small molecules as HCV inhibitors.

Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein

Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking

Recent Advance in Antiviral Drugs for Hepatitis C.

3D-QSAR and Molecular Docking Studies on Designing Inhibitors of the Hepatitis C Virus NS5B Polymerase

HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.

Recent progress of hepatitis virus C targets and small molecule inhibitors

Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

Combined 3D‐QSAR, Molecular Docking, Molecular Dynamics Simulation, and Binding Free Energy Calculation Studies on the 5‐hydroxy‐2h‐pyridazin‐3‐one Derivatives As HCV NS5B Polymerase Inhibitors

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C